ctDNA in NSCLC: Review Maps Current Evidence for MRD Detection and Treatment Monitoring
This review from BMJ Oncology summarises the growing role of ctDNA as a predictive and prognostic tool in non-small cell lung cancer management, covering early detection, molecular residual disease monitoring, treatment response assessment, and resistance identification. The review highlights liquid biopsy's potential for real-time tumour assessment but remains a high-level overview without new data.
The original study
Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection.
- Authors
- Jimenez-Munarriz B, Urtecho B, Rabey MR, Leighl NB
- Journal
- BMJ oncology
- PMID
- 41836517
Original abstract
Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.